<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03300804</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00041236</org_study_id>
    <secondary_id>1U19AT003266-01</secondary_id>
    <nct_id>NCT03300804</nct_id>
  </id_info>
  <brief_title>Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS)</brief_title>
  <acronym>TCM-IBS</acronym>
  <official_title>Dose Escalation Trial Of Traditional Chinese Medicine For Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a 20- herb formulation, as a well&#xD;
      characterised extract, is efficacious in treating irritable bowel syndrome (IBS) and also to&#xD;
      identify efficacious and safe dosage of the formulation in treating IBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Specific aims of the project are:&#xD;
&#xD;
        1. To determine whether a 20- herb formulation improves pain/ discomfort and disturbed&#xD;
           bowel frequency in patients with Irritable Bowel Syndrome who have been disappointed&#xD;
           with current conventional Western medicine.&#xD;
&#xD;
        2. To identify an optimal dosage of the 20- herb formulation that is safe and well&#xD;
           tolerated for up to 8 weeks of treatment, among 2 dosages. This is determined by relief&#xD;
           of symptoms of IBS in a dose escalation, placebo-controlled double- blind randomized&#xD;
           clinical trial, in conjunction with indices of safety and tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global IBS symptom improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary endpoint for this study is the efficacy at the 8 week followup visit of the herbal formulations, which is defined by the patient's global assessment of the IBS symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Bowel Symptom Scale (BSS):</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Bowel Symptom Scale will be used to assess changes in individual IBS and global IBS symptoms during the course of illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quality of Life generic (SF-36), will be used for assessment of quality of life in response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS-QoL</measure>
    <time_frame>8 weeks</time_frame>
    <description>Disease-specific (IBS-QoL) will be used for assessment of quality of life in response to treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>20-herb formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active herb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo herb formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20-herb formulation</intervention_name>
    <description>Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks</description>
    <arm_group_label>20-herb formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo herb formulation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18- 75&#xD;
&#xD;
          -  All IBS patients attending the Gastroenterology Clinic of the Prince Of Wales Hospital&#xD;
             of Hong Kong.&#xD;
&#xD;
          -  IBS diagnosed by Rome III criteria:&#xD;
&#xD;
               -  Recurrent abdominal pain or discomfort at least three days per month in the&#xD;
                  previous three months&#xD;
&#xD;
               -  Symptoms onset at least six months prior to diagnose&#xD;
&#xD;
               -  Pain or discomfort associated with two or more of the following:&#xD;
&#xD;
                    1. Improvement with defecation&#xD;
&#xD;
                    2. Onset associated with change in frequency of stool&#xD;
&#xD;
                    3. Onset associated with a change in form (appearance) of stool&#xD;
&#xD;
          -  Normal colonic evaluation (colonoscopy or barium enema) in past 5 years&#xD;
&#xD;
          -  No &quot;global symptom improvement&quot; as rated by patients (see below) at screening and&#xD;
             during the two- week run- in period to baseline&#xD;
&#xD;
          -  Normal full blood count, liver function test and renal function test.&#xD;
&#xD;
               -  Informed written consent for participation into study.&#xD;
&#xD;
               -  Ethical approval will be obtained from the Joint CUHK-NTEC Clinical Research&#xD;
                  Ethics Committee as well as the IRB of UMB.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past or present history of organic disease of gastrointestinal tract (e.g. colorectal&#xD;
             cancer, advanced colonic polyp, celiac disease, inflammatory bowel disease, peptic&#xD;
             ulcer and previous gastrointestinal surgery). (Note: those with polyps removed during&#xD;
             colonoscopy can be included, as long as no known polyps remained.&#xD;
&#xD;
          -  Systemic diseases that cause diarrhea or constipation (e.g. thyroid disease, diabetic&#xD;
             neuropathy)&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Severe liver disease (e.g. cirrhosis, chronic active hepatitis)&#xD;
&#xD;
          -  Renal impairment (serum creatinine level &gt; 150mmol/L)&#xD;
&#xD;
          -  Women who are pregnant, lactating or not practicing proper contraception&#xD;
&#xD;
          -  Known hypersensitivity to herbal medicine&#xD;
&#xD;
          -  Concommitant use of prescription antidepressant medication&#xD;
&#xD;
          -  Current alcoholism and drug use&#xD;
&#xD;
          -  Current psychiatric illness or dementia&#xD;
&#xD;
          -  Fever or severe illness at baseline (week 0).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Berman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Gastroenterelogy Clinic Of the Prince Of Wales, Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Brian Berman</investigator_full_name>
    <investigator_title>Director of Research Center for Integrative Medicine, University of Maryland</investigator_title>
  </responsible_party>
  <keyword>IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

